Glibenclamide pharmacokinetics in acarbose-treated type 2 diabetics
Tóm tắt
A single dose of glibenclamide 5 mg was administered to six Type 2 diabetics, randomly treated for 7 days either with acarbose (3×100 mg daily) or with placebo. The serum concentration of the drug was measured for 10 h. Peak concentrations, times-to-peak concentration, elimination half-lives and the extent of bioavailability of the drug were not significantly modified by acarbose. The combined administration of glibenclamide and acarbose resulted in a modest improvement in the blood glucose profile after breakfast and lunch, together with a significant diminution in plasma insulin. Thus, acarbose appears a useful additional treatment for Type 2 diabetics already receiving sulphonylurea derivatives.
Tài liệu tham khảo
Sachse G, Willms B (1979) Effect of the α-glucosidase inhibitor BAY-g-5421 on blood glucose control of sulfonylureatreated diabetics and insulin-treated diabetics. Diabetologia 17:187–190
Gerard J, Luyckx AS, Lefebvre PJ (1981) Improvement of metabolic control in insulin dependent diabetics treated with the α-glucosidase inhibitor acarbose for two months. Diabetologia 21:446–451
Creutzfeldt W (1982) First International Symposium on Acarbose. Effects on carbohydrate and fat metabolism. Excerpta Medica, Amsterdam Oxford Princeton. ICS 594
Schmidt D, Frommer W, Junge B, Müller L, Wingender W, Truscheit E (1977) α-Glucosidase inhibitors. Naturwissenschaften 64:535–536
Puls W, Keup U, Krause JP, Thomas G, Hoffmeister F (1977) Glucosidase inhibitors. A new approach to the treatment of diabetes, obesity and hyperlipoproteinaemia. Naturwissenschaften 64:536–537
Shima K, Tanaka A, Ikegami H, Tabata M, Sawazaki N, Kumahara Y (1983) Effect of dietary fiber, glucomannan, on absorption of sulfonylurea in man. Horm Metab Res 15:1–3
Lefebvre PJ, Luyckx AS (1976) The breakfast tolerance test: a return to physiology. Diab Metab 2:15–19
Schmidt FH (1961) Enzymatic determination of glucose and fructose simultaneously. Klin Wochenschr 39:1244–1249
Hales CN, Randle PJ (1963) Immunoassay of insulin with insulin antibody precipitate. Biochem J 88:137–146
Luyckx AS (1972) Immunoassays for glucagon. In: Lefebvre PJ, Unger RH (eds) Glucagon, molecular physiology, clinical and therapeutic implications. Pergamon Press, Oxford, 285–298
Malangeau P, Bourdon R, Nicaise AM, Masson B (1963) Dosage des acides aminés dans les liquides de l'organisme. Ann Biol Clin 21:1
Worlicek H, Schneider M, Kolb S, Sailer D (1982) Treatment of non-insulin dependent diabetic adults with acarbose: the effect of dosage division. In: Creutzfeld W (ed) First International Symposium on Acarbose. Effects on carbohydrate and fat metabolism. Excerpta Medica, Amsterdam Oxford Princeton, pp 313–316
Aubell R, Boehme K, Berchtold P (1982) One-year acarbose treatment of diabetic out-patients. Multicentre study part II: efficacy. In: Creutzfeldt W (ed) First International Symposium on Acarbose. Effects on carbohydrate and fat metabolism. Excerpta Medica, Amsterdam Oxford Princeton, pp 363–366
Vessby B, Lithell H, Abelin J (1982) Addition of acarbose to diet and oral antidiabetic agents in maturity-onset diabetes: a short-term cross-over metabolic-ward study. In: Creutzfeldt W (ed) First International Symposium on Acarbose. Effects on carbohydrate and fat metabolism. Excerpta Medica, Amsterdam Oxford Princeton, pp 309–312
Vierhapper H, Bratusch-Marrain P, Waldhäusl W (1982) Effect of long-term treatment with acarbose (BAY g 5421) on postprandial blood glucose concentrations in type II diabetics. In: Creutzfeldt W (ed) First International Symposium on Acarbose. Effects on carbohydrate and fat metabolism. Excerpta Medica, Amsterdam Oxford Princeton, 357–359
Hillebrand I, Graefe KH, Bischoff H, Franck G, Raemsch KD, Berchtold P (1981) Serum digoxin- and propranolol levels during acarbose-treatment. Diabetologia 21:282